Vaccines Market
Research Code:MRHC - 104377
Sku:MRHC - 104377
Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence (Multivalent, Monovalent Vaccines) - Global Forecast to 2027
- Report ID: MRHC - 104377
- Pages: 231
- Feb-2020
- Formats*: PDF
- Category: Healthcare
- Delivery: 2 to 4 Hours
We are in the phase of updating this report by analysing the impact of COVID-19 on this market.
The global vaccines market is expected to grow at a CAGR of ~5.2% from 2019 to 2027 to reach $62.2 billion by 2027. The high prevalence of infectious diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, and a strong pipeline for vaccines are the key factors driving steady growth in the global vaccines market. Furthermore, increasing epidemic potentials, growing focus on therapeutic vaccines, and emerging markets offer significant revenue growth opportunities for the players operating in this market.
Increasing focus of government agencies on immunization programs to propel the growth of vaccines market
In recent years, government agencies across the globe are focusing on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered as the first line of defense to avoid an endemic and pandemic situation that leads to healthcare emergency situation. Hence, some governments heavily focus on vaccination programs like Flu vaccination, Japanese Encephalitis etc. while many partners with the private sector and private companies for enhancing vaccine R&D for diseases. For instance,
- In 2019, WHO launched Polio Endgame Strategy 2019-2023 to immunize every child and eradicate polio completely. The major aims of the program include stopping of all vaccine-preventable poliovirus outbreaks and eliminate the risk of re-emergence of polio to facilitate rapid response and immunization in case of outbreaks.
- In 2018, Indian government launched the Comprehensive multi-year plan (2018-22) to reduce mortality and morbidity due to vaccine-preventable diseases and to ensure vaccination coverage of more than 90% in the country.
Click here to Download Sample Report NOW!!
Strong vaccine pipeline and growing focus of the key pharmaceutical players to develop innovative vaccines is a major driver for the global vaccines market
Although vaccine development has received huge support from pharmaceutical industry and governments over the last decade for eradication of infectious diseases, many preventable diseases still cost millions of lives and billions of dollars every year. Vaccine manufacturers and key stakeholders are addressing this concern by increasing their focus on developing new innovative vaccines. According to the World Health Organization (WHO), as of September 2018, across all cases of infectious diseases, around 463 products are in pipeline. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2018, around 1,100 medicines and vaccines were in development stage in the U.S. for cancer treatment as compared to 900 medicines and vaccines in 2012.
In addition, Access to Medicine Foundation (Netherlands) states that leading players operating in the vaccines market have several vaccines in pipeline for various indications, which are expected to reach market in the coming 5 to 6 years. As per the estimations, in 2017, GlaxoSmithKline plc (U.K.) had around 25 vaccines in development phase, Johnson & Johnson (U.S.) had 14, and Sanofi (France) had 13 projects in pipeline.
Key findings of the global vaccines market study:
Pneumococcal disease segment commanded the largest share of the overall vaccines market in 2019
Factors such as rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, and sinusitis; development of quality vaccines such as PPSV23; and various initiatives by government organizations and private sectors to prevent and control outbreak of pneumococcal diseases contributed to the largest share of this segment in the overall vaccines market.
Intramuscular route of administration to dominate the vaccines market through 2027
Intramuscular vaccines commanded the largest share of the overall vaccines market in 2019. The large share of this segment is mainly attributed to factors such as easy accessibility, unaided administration, larger muscle capacity, and precise control of dose and administration rate.
Subunit & conjugate vaccines to dominate the overall vaccines market through 2027
Subunit and conjugate vaccines are the major antigen types used to prepare vaccines and hence commanded the largest share of the global vaccines market in 2019. The greater adoption of these vaccines is mainly due to long term immunity and the low-risk rate associated with the subunit vaccines along with the increasing demand for immunization.
Multivalent vaccines to register the fastest growth in the vaccines market by 2027
The multivalent vaccines accounted for the largest share of this market in 2019 and is expected to grow at the fastest CAGR during the forecast period. New product launches and increasing focus of key players to design multivalent vaccines are the major factors driving the growth of multivalent vaccines market.
Asia-Pacific: The fastest-growing regional market
North America commanded the largest share of the global vaccines market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia Pacific region is expected to grow at the fastest CAGR during the forecast period owing to large population of patients and growing government support for immunization programs. In addition, improvement in vaccine production facilities and increasing investments by the major players in this region, increasing disposable income, and growing awareness about health further supports the market growth.
Key Players
The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2016-2019). The key players profiled in the global vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca (U.K.).
Scope of the Report:
Global Vaccines Market, by Indication
- Pneumococcal Disease
- Influenza
- DTP
- Human Papilloma Virus (HPV)
- Meningococcal Disease
- Poliomyelitis (Polio)
- MMR
- Rotavirus
- Hepatitis
- Other Indications
(Note: Other indications include varicella, herpes zoster vaccines, chlorella, and rabies vaccines.)
Global Vaccines Market, by Route of Administration
- Intramuscular (IM)
- Subcutaneous (SC)
- Oral
- Other Routes
(Note: Other routes include intradermal (ID), transcutaneous (TC), and nasal route)
Global Vaccines Market, by Type/Antigen
- Subunit & Conjugate Vaccines
- Inactivated vaccines
- Live Attenuated Vaccines
- Toxoid vaccines
- Combination Vaccines
Global Vaccines Market, by Valence
- Multivalent Vaccines
- Monovalent vaccines
Global Vaccines Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- Japan
- China
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Additional Insights-
In addition to global opportunity analysis and market forecasts, the Vaccines Market study provides detailed insights on regulatory analysis, product pipeline analysis, pricing analysis, and unmet need analysis. The study also showcases competitive benchmarking for top market players, by product and geography. The competitive landscape of this study also provides market share analysis, by market players and vaccines brand.
Key questions answered in the report-
What is Vaccines Market?
What are the market size forecasts and CAGR from the period 2019-2027?
Which are the largest and fastest growing vaccine types of the market?
What are the major drivers of the market?
What are the major restraints of the global vaccines market?
What are the major opportunities in the global market?
What are the major challenges in the global market?
Who are the major key players operating in the global vaccines market?
What are high growth countries/regions in the market?
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2 Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market insights
4.1. Market Overview
4.2. Drivers
4.2.1. Strong Vaccines Pipeline
4.2.2. Rising Adoption of Vaccination
4.2.3. Increasing Government Focus on Immunization Programs
4.2.4. Technological Progress in Vaccine Administration
4.3. Restraints
4.3.1. High Cost Associated with Vaccine Development
4.3.2. Longer Timelines for Vaccine Manufacturing
4.4. Opportunities
4.4.1. Increasing Epidemic Potentials
4.4.2. Growing Focus on Therapeutic Vaccines
4.4.3. Growth Prospects in Emerging Markets
4.4.4. Increasing Use of Adjuvants in Vaccines
4.5. Challenges
4.5.1. Product Recalls
4.5.2. Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.1. Introduction
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papilloma Virus (HPV)
6.5. DTP
6.6. Meningococcal Disease
6.7. MMR
6.8. Rotavirus
6.9. Poliomyelitis (Polio)
6.10. Hepatitis
6.11. Other Indications
7. Global Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other (Routes of Administration)
8. Global Vaccines Market, by Type/Antigen
8.1. Introduction
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
8.6. Combination Vaccines
9. Global Vaccines Market, by Valence
9.1. Introduction
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Global Vaccines Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis
11.4.1. Market Share Analysis, by Company
11.4.2. Market Share Analysis, by Product
12. Company Profiles
12.1. Sanofi
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Pipeline Products
12.1.5. Strategic Developments
12.2. Merck & Co., Inc.
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.2.4. Pipeline Products
12.2.5. Strategic Developments
12.3. GlaxoSmithKline Plc.
12.3.1. Business Overview
12.3.2. Financial Overview
12.3.3. Product Portfolio
12.3.4. Pipeline Products
12.3.5. Strategic Developments
12.4. Pfizer, Inc.
12.4.1. Business Overview
12.4.2. Financial Overview
12.4.3. Product Portfolio
12.4.4. Pipeline Products
12.4.5. Strategic Developments
12.5. Johnson & Johnson
12.5.1. Business Overview
12.5.2. Financial Overview
12.5.3. Product Portfolio
12.5.4. Pipeline Products
12.5.5. Strategic Developments
12.6. Daiichi Sankyo Co., Ltd.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.3. Product Portfolio
12.6.4. Pipeline Products
12.7. Takeda Pharmaceutical Company Limited
12.7.1. Business Overview
12.7.2. Financial Overview
12.7.3. Product Portfolio
12.7.4. Pipeline Products
12.7.5. Strategic Developments
12.8. CSL Limited
12.8.1. Business Overview
12.8.2. Financial Overview
12.8.3. Product Portfolio
12.8.4. Pipeline Products
12.8.5. Strategic Developments
12.9. Emergent BioSolutions Inc.
12.9.1. Business Overview
12.9.2. Financial Overview
12.9.3. Product Portfolio
12.9.4. Pipeline Products
12.9.5. Strategic Developments
12.10. AstraZeneca
12.10.1.Business Overview
12.10.2.Financial Overview
12.10.3.Product Portfolio
12.10.4.Pipeline Products
13. Appendix
13.1. Questionnaire
13.2. Available Customization
List of Tables
Table 1 Global Vaccines Market Drivers: Impact Analysis (2019-2025)
Table 2 Key Government Regulatory Agencies
Table 3 List of Some of the Promising Vaccines in the Pipeline
Table 4 ASP of Key Vaccines, by Region ($ Per Unit)
Table 5 Global Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 6 Overview: Pneumococcal Disease
Table 7 Pneumococcal Diseases: Pipelined Vaccines
Table 8 Key Companies offering Pneumococcal Vaccines
Table 9 Pneumococcal Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 10 Overview: influenza Disease
Table 11 Influenza Diseases: Pipelined Vaccines
Table 12 Key Companies offering influenza Vaccines
Table 13 Influenza Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 14 Overview: HPV Disease
Table 15 HPV Vaccine Cost (2017)
Table 16 Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 17 Overview: Diphtheria, Tetanus, Pertussis Disease
Table 18 Global Supply of D&T by Product Group
Table 19 Key Companies offering DTP Vaccines
Table 20 DTP Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 21 Overview: Meningococcal Disease
Table 22 Marketed Meningococcal Vaccine Combinations
Table 23 Key Companies offering Meningococcal Vaccines
Table 24 Meningococcal Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 25 Overview: Measles, Mumps and Rubella Disease
Table 26 Key Companies offering MMR Vaccines
Table 27 MMR Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 28 Overview: Rotavirus Disease
Table 29 Key Companies offering Rotavirus Vaccines
Table 30 Rotavirus Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 31 Overview: Poliomyelitis Disease
Table 32 Polio Cases and Endemic Countries
Table 33 Key Companies offering Polio Vaccines
Table 34 Polio Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 35 Overview: Hepatitis A
Table 36 Overview: Hepatitis B
Table 37 Key Companies offering Hepatitis Vaccines
Table 38 Hepatitis Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 39 Other Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 40 Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 41 Intramuscular Sites of Vaccine Administration, by Age Group
Table 42 Vaccines for intramuscular Administration
Table 43 Key Companies offering intramuscular Vaccines
Table 44 Intramuscular Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 45 Site of Administration of Subcutaneous Vaccines by Age Group
Table 46 Vaccines for Subcutaneous Administration
Table 47 Key Companies offering Subcutaneous Vaccines
Table 48 Subcutaneous Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 49 Key Companies offering Oral Vaccines
Table 50 Oral Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 51 Other (Route of Administration) Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 52 Types of Vaccines, by Antigen
Table 53 Global Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 54 Companies offering Subunit & Conjugate Vaccines
Table 55 Subunit & Conjugate Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 56 Companies Offering Inactivated Vaccines
Table 57 Inactivated Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 58 Companies Offering Live Attenuated Vaccines
Table 59 Live Attenuated Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 60 Toxoid Vaccines Used in the Vaccination Schedule
Table 61 Companies Offering Toxoid Vaccines
Table 62 Toxoid Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 63 Companies offering Combination Vaccines
Table 64 Combination Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 65 Global Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 66 Available Multivalent Vaccines for Children
Table 67 Companies offering Multivalent Vaccines
Table 68 Multivalent Vaccines Market Size, by Region/Country, 2016–2025 ($Million)
Table 69 Malaria, Ebola and Dengue Disease Vaccines in Pipeline
Table 70 Companies offering Monovalent Vaccines
Table 71 Monovalent Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 72 Global Vaccines Market Size, by Country/ Region, 2017-2027 ($Million)
Table 73 North America: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 74 North America: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 75 North America: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 76 North America: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 77 North America: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 78 Influenza Burden in the U.S., 2012-2018
Table 79 Pfizer Inc. Vaccine Pipeline in the U.S.
Table 80 U.S.: Macroindicators
Table 81 U.S.: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 82 U.S.: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 83 U.S.: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 84 U.S.: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 85 Canada: Macroindicators
Table 86 Canada: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 87 Canada: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 88 Canada: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 89 Canada: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 90 Europe: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 91 Europe: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 92 Europe: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 93 Europe: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 94 Europe: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 95 Germany: Macroindicators
Table 96 Germany: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 97 Germany: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 98 Germany: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 99 Germany: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 100 U.K.: Macroindicators
Table 101 U.K.: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 102 U.K.: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 103 U.K.: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 104 U.K.: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 105 France: Macroindicators
Table 106 France: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 107 France: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 108 France: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 109 France: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 110 Italy: Macroindicators
Table 111 Italy: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 112 Italy: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 113 Italy: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 114 Italy: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 115 Spain: Macroindicators
Table 116 Spain: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 117 Spain: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 118 Spain: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 119 Spain: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 120 RoE: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 121 RoE: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 122 RoE: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 123 RoE: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 124 Asia-Pacific: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 125 Asia-Pacific: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 126 Asia-Pacific: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 127 Asia-Pacific: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 128 Asia-Pacific: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 129 Japan: Macroindicators
Table 130 Japan: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 131 Japan: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 132 Japan: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 133 Japan: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 134 China: Macroindicators
Table 135 China: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 136 China: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 137 China: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 138 China: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 139 Cost of Some of the Vaccines in India
Table 140 India: Macroindicators
Table 141 India: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 142 India: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 143 India: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 144 India: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 145 RoAPAC: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 146 RoAPAC: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 147 RoAPAC: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 148 RoAPAC: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 149 Latin America: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 150 Latin America: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 151 Latin America: Vaccines Market Size, by Type, 2016–2025 ($Million)
Table 152 Latin America: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 153 Middle East & Africa: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 154 Middle East & Africa: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 155 Middle East & Africa: Vaccines Market Size, by Type, 2016–2025 ($Million)
Table 156 Middle East & Africa: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 157 Number of Developments by the Major Players During 2016-2019
Table 158 Vaccines Market: Product Competitive Benchmarking
Table 159 Vaccines Market: Geographic Competitive Benchmarking
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives interviewed
Figure 5 Breakdown of Primary interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth forecast Approach
Figure 7 Global Vaccines Market, by indication, 2019-2027 ($Million)
Figure 8 Global Vaccines Market Size, by Route of Administration, 2019-2027 ($Million)
Figure 9 Global Vaccines Market Size, by Antigen/Type, 2019-2027 ($Million)
Figure 10 Multivalent Vaccine Segment Will Dominate the Global Vaccines Market During the forecast Period
Figure 11 Vaccines Market, by Region
Figure 12 Products in Pipeline for infectious Diseases: 2018
Figure 13 Vaccines Projects in Pipeline: 2017
Figure 14 Disposable income Per Capita of China (in $): 2014-2018
Figure 15 Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010-2018
Figure 16 Decrease in Number of Tuberculosis Deaths: 2012-2017
Figure 17 Therapeutic Vaccines in Pipeline for Cancer: 2011 and 2018
Figure 18 New Cancer Cases in Asia, Latin America and Caribbean: 2018-2040
Figure 19 Vaccines Market, Product Pipeline, by Phase (2018)
Figure 20 Global Vaccines Market Size, by indication, 2019–2027 ($Million)
Figure 21 Influenza Vaccines Distribution: 2016-2019
Figure 22 Forecasted Global Demand of DTwP Vaccines: 2018-2032
Figure 23 MMR Vaccines Supply: 2016-2018
Figure 24 Global Vaccination Coverage for Rotavirus: 2010-2018
Figure 25 U.S. Funding for Global Polio: 2013-2019
Figure 26 Different Routes of Vaccine Administration
Figure 27 Vaccines Market Size, by Route of Administration, 2019–2027 ($Million)
Figure 28 Global Vaccines Market Size, by Type, 2019–2027 ($Million)
Figure 29 Global Vaccines Market Size, by Valence, 2019–2027 ($Million)
Figure 30 Global Vaccines Size, by Region, 2019-2027 ($Million)
Figure 31 North America: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 32 U.S. Funding for Global Polio: 2013-2019
Figure 33 Europe: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 34 Increase in Immunization After Mandatory Vaccination
Figure 35 Increase in Number of Registered influenza Cases (2015-2019)
Figure 36 Spain: increase in Number of Biotechnology Companies (2010-2016)
Figure 37 Asia-Pacific: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 38 India: Increasing Health Expenditure (2010-2018)
Figure 39 Cancer incidence in Middle East and Africa: 2012 and 2030
Figure 40 Key Growth Strategies Adopted by Leading Players -2016-2019
Figure 41 Global Vaccines Market Share, by Key Players, 2018 (%)
Figure 42 Vaccines Market Share Analysis, by Brand (2018)
Figure 43 Sanofi: Financial Overview (2016-2018)
Figure 44 Merck & Co., Inc.: Financial Overview (2016-2018)
Figure 45 GlaxoSmithKline Plc (GSK): Financial Overview (2016-2018)
Figure 46 Pfizer Inc.: Financial Overview (2016-2018)
Figure 47 Johnson & Johnson (J&J): Financial Overview (2016-2018)
Figure 48 Daichi Sankyo Co., Ltd.: Financial Overview (2016-2018)
Figure 49 Takeda Pharmaceutical: Financial Overview (2017-2019)
Figure 50 CSL Limited: Financial Overview (2017-2019)
Figure 51 Emergent BioSolutions Inc.: Financial Overview (2016-2018)
Figure 52 AstraZeneca: Financial Overview (2016-2018)
This website is secure and we do not share your personal information with any third party. Privacy Policy
The global vaccines market is expected to grow at a CAGR of ~5.2% from 2019 to 2027 to reach $62.2 billion by 2027. The high prevalence of infectious diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, and a strong pipeline for vaccines are the key factors driving steady growth in the global vaccines market. Furthermore, increasing epidemic potentials, growing focus on therapeutic vaccines, and emerging markets offer significant revenue growth opportunities for the players operating in this market.
Increasing focus of government agencies on immunization programs to propel the growth of vaccines market
In recent years, government agencies across the globe are focusing on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered as the first line of defense to avoid an endemic and pandemic situation that leads to healthcare emergency situation. Hence, some governments heavily focus on vaccination programs like Flu vaccination, Japanese Encephalitis etc. while many partners with the private sector and private companies for enhancing vaccine R&D for diseases. For instance,
- In 2019, WHO launched Polio Endgame Strategy 2019-2023 to immunize every child and eradicate polio completely. The major aims of the program include stopping of all vaccine-preventable poliovirus outbreaks and eliminate the risk of re-emergence of polio to facilitate rapid response and immunization in case of outbreaks.
- In 2018, Indian government launched the Comprehensive multi-year plan (2018-22) to reduce mortality and morbidity due to vaccine-preventable diseases and to ensure vaccination coverage of more than 90% in the country.
Click here to Download Sample Report NOW!!
Strong vaccine pipeline and growing focus of the key pharmaceutical players to develop innovative vaccines is a major driver for the global vaccines market
Although vaccine development has received huge support from pharmaceutical industry and governments over the last decade for eradication of infectious diseases, many preventable diseases still cost millions of lives and billions of dollars every year. Vaccine manufacturers and key stakeholders are addressing this concern by increasing their focus on developing new innovative vaccines. According to the World Health Organization (WHO), as of September 2018, across all cases of infectious diseases, around 463 products are in pipeline. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2018, around 1,100 medicines and vaccines were in development stage in the U.S. for cancer treatment as compared to 900 medicines and vaccines in 2012.
In addition, Access to Medicine Foundation (Netherlands) states that leading players operating in the vaccines market have several vaccines in pipeline for various indications, which are expected to reach market in the coming 5 to 6 years. As per the estimations, in 2017, GlaxoSmithKline plc (U.K.) had around 25 vaccines in development phase, Johnson & Johnson (U.S.) had 14, and Sanofi (France) had 13 projects in pipeline.
Key findings of the global vaccines market study:
Pneumococcal disease segment commanded the largest share of the overall vaccines market in 2019
Factors such as rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, and sinusitis; development of quality vaccines such as PPSV23; and various initiatives by government organizations and private sectors to prevent and control outbreak of pneumococcal diseases contributed to the largest share of this segment in the overall vaccines market.
Intramuscular route of administration to dominate the vaccines market through 2027
Intramuscular vaccines commanded the largest share of the overall vaccines market in 2019. The large share of this segment is mainly attributed to factors such as easy accessibility, unaided administration, larger muscle capacity, and precise control of dose and administration rate.
Subunit & conjugate vaccines to dominate the overall vaccines market through 2027
Subunit and conjugate vaccines are the major antigen types used to prepare vaccines and hence commanded the largest share of the global vaccines market in 2019. The greater adoption of these vaccines is mainly due to long term immunity and the low-risk rate associated with the subunit vaccines along with the increasing demand for immunization.
Multivalent vaccines to register the fastest growth in the vaccines market by 2027
The multivalent vaccines accounted for the largest share of this market in 2019 and is expected to grow at the fastest CAGR during the forecast period. New product launches and increasing focus of key players to design multivalent vaccines are the major factors driving the growth of multivalent vaccines market.
Asia-Pacific: The fastest-growing regional market
North America commanded the largest share of the global vaccines market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia Pacific region is expected to grow at the fastest CAGR during the forecast period owing to large population of patients and growing government support for immunization programs. In addition, improvement in vaccine production facilities and increasing investments by the major players in this region, increasing disposable income, and growing awareness about health further supports the market growth.
Key Players
The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2016-2019). The key players profiled in the global vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca (U.K.).
Scope of the Report:
Global Vaccines Market, by Indication
- Pneumococcal Disease
- Influenza
- DTP
- Human Papilloma Virus (HPV)
- Meningococcal Disease
- Poliomyelitis (Polio)
- MMR
- Rotavirus
- Hepatitis
- Other Indications
(Note: Other indications include varicella, herpes zoster vaccines, chlorella, and rabies vaccines.)
Global Vaccines Market, by Route of Administration
- Intramuscular (IM)
- Subcutaneous (SC)
- Oral
- Other Routes
(Note: Other routes include intradermal (ID), transcutaneous (TC), and nasal route)
Global Vaccines Market, by Type/Antigen
- Subunit & Conjugate Vaccines
- Inactivated vaccines
- Live Attenuated Vaccines
- Toxoid vaccines
- Combination Vaccines
Global Vaccines Market, by Valence
- Multivalent Vaccines
- Monovalent vaccines
Global Vaccines Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- Japan
- China
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Additional Insights-
In addition to global opportunity analysis and market forecasts, the Vaccines Market study provides detailed insights on regulatory analysis, product pipeline analysis, pricing analysis, and unmet need analysis. The study also showcases competitive benchmarking for top market players, by product and geography. The competitive landscape of this study also provides market share analysis, by market players and vaccines brand.
Key questions answered in the report-
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2 Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market insights
4.1. Market Overview
4.2. Drivers
4.2.1. Strong Vaccines Pipeline
4.2.2. Rising Adoption of Vaccination
4.2.3. Increasing Government Focus on Immunization Programs
4.2.4. Technological Progress in Vaccine Administration
4.3. Restraints
4.3.1. High Cost Associated with Vaccine Development
4.3.2. Longer Timelines for Vaccine Manufacturing
4.4. Opportunities
4.4.1. Increasing Epidemic Potentials
4.4.2. Growing Focus on Therapeutic Vaccines
4.4.3. Growth Prospects in Emerging Markets
4.4.4. Increasing Use of Adjuvants in Vaccines
4.5. Challenges
4.5.1. Product Recalls
4.5.2. Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.1. Introduction
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papilloma Virus (HPV)
6.5. DTP
6.6. Meningococcal Disease
6.7. MMR
6.8. Rotavirus
6.9. Poliomyelitis (Polio)
6.10. Hepatitis
6.11. Other Indications
7. Global Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other (Routes of Administration)
8. Global Vaccines Market, by Type/Antigen
8.1. Introduction
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
8.6. Combination Vaccines
9. Global Vaccines Market, by Valence
9.1. Introduction
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Global Vaccines Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis
11.4.1. Market Share Analysis, by Company
11.4.2. Market Share Analysis, by Product
12. Company Profiles
12.1. Sanofi
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Pipeline Products
12.1.5. Strategic Developments
12.2. Merck & Co., Inc.
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.2.4. Pipeline Products
12.2.5. Strategic Developments
12.3. GlaxoSmithKline Plc.
12.3.1. Business Overview
12.3.2. Financial Overview
12.3.3. Product Portfolio
12.3.4. Pipeline Products
12.3.5. Strategic Developments
12.4. Pfizer, Inc.
12.4.1. Business Overview
12.4.2. Financial Overview
12.4.3. Product Portfolio
12.4.4. Pipeline Products
12.4.5. Strategic Developments
12.5. Johnson & Johnson
12.5.1. Business Overview
12.5.2. Financial Overview
12.5.3. Product Portfolio
12.5.4. Pipeline Products
12.5.5. Strategic Developments
12.6. Daiichi Sankyo Co., Ltd.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.3. Product Portfolio
12.6.4. Pipeline Products
12.7. Takeda Pharmaceutical Company Limited
12.7.1. Business Overview
12.7.2. Financial Overview
12.7.3. Product Portfolio
12.7.4. Pipeline Products
12.7.5. Strategic Developments
12.8. CSL Limited
12.8.1. Business Overview
12.8.2. Financial Overview
12.8.3. Product Portfolio
12.8.4. Pipeline Products
12.8.5. Strategic Developments
12.9. Emergent BioSolutions Inc.
12.9.1. Business Overview
12.9.2. Financial Overview
12.9.3. Product Portfolio
12.9.4. Pipeline Products
12.9.5. Strategic Developments
12.10. AstraZeneca
12.10.1.Business Overview
12.10.2.Financial Overview
12.10.3.Product Portfolio
12.10.4.Pipeline Products
13. Appendix
13.1. Questionnaire
13.2. Available Customization
List of Tables
Table 1 Global Vaccines Market Drivers: Impact Analysis (2019-2025)
Table 2 Key Government Regulatory Agencies
Table 3 List of Some of the Promising Vaccines in the Pipeline
Table 4 ASP of Key Vaccines, by Region ($ Per Unit)
Table 5 Global Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 6 Overview: Pneumococcal Disease
Table 7 Pneumococcal Diseases: Pipelined Vaccines
Table 8 Key Companies offering Pneumococcal Vaccines
Table 9 Pneumococcal Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 10 Overview: influenza Disease
Table 11 Influenza Diseases: Pipelined Vaccines
Table 12 Key Companies offering influenza Vaccines
Table 13 Influenza Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 14 Overview: HPV Disease
Table 15 HPV Vaccine Cost (2017)
Table 16 Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 17 Overview: Diphtheria, Tetanus, Pertussis Disease
Table 18 Global Supply of D&T by Product Group
Table 19 Key Companies offering DTP Vaccines
Table 20 DTP Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 21 Overview: Meningococcal Disease
Table 22 Marketed Meningococcal Vaccine Combinations
Table 23 Key Companies offering Meningococcal Vaccines
Table 24 Meningococcal Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 25 Overview: Measles, Mumps and Rubella Disease
Table 26 Key Companies offering MMR Vaccines
Table 27 MMR Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 28 Overview: Rotavirus Disease
Table 29 Key Companies offering Rotavirus Vaccines
Table 30 Rotavirus Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 31 Overview: Poliomyelitis Disease
Table 32 Polio Cases and Endemic Countries
Table 33 Key Companies offering Polio Vaccines
Table 34 Polio Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 35 Overview: Hepatitis A
Table 36 Overview: Hepatitis B
Table 37 Key Companies offering Hepatitis Vaccines
Table 38 Hepatitis Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 39 Other Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 40 Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 41 Intramuscular Sites of Vaccine Administration, by Age Group
Table 42 Vaccines for intramuscular Administration
Table 43 Key Companies offering intramuscular Vaccines
Table 44 Intramuscular Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 45 Site of Administration of Subcutaneous Vaccines by Age Group
Table 46 Vaccines for Subcutaneous Administration
Table 47 Key Companies offering Subcutaneous Vaccines
Table 48 Subcutaneous Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 49 Key Companies offering Oral Vaccines
Table 50 Oral Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 51 Other (Route of Administration) Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 52 Types of Vaccines, by Antigen
Table 53 Global Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 54 Companies offering Subunit & Conjugate Vaccines
Table 55 Subunit & Conjugate Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 56 Companies Offering Inactivated Vaccines
Table 57 Inactivated Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 58 Companies Offering Live Attenuated Vaccines
Table 59 Live Attenuated Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 60 Toxoid Vaccines Used in the Vaccination Schedule
Table 61 Companies Offering Toxoid Vaccines
Table 62 Toxoid Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 63 Companies offering Combination Vaccines
Table 64 Combination Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 65 Global Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 66 Available Multivalent Vaccines for Children
Table 67 Companies offering Multivalent Vaccines
Table 68 Multivalent Vaccines Market Size, by Region/Country, 2016–2025 ($Million)
Table 69 Malaria, Ebola and Dengue Disease Vaccines in Pipeline
Table 70 Companies offering Monovalent Vaccines
Table 71 Monovalent Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 72 Global Vaccines Market Size, by Country/ Region, 2017-2027 ($Million)
Table 73 North America: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 74 North America: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 75 North America: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 76 North America: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 77 North America: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 78 Influenza Burden in the U.S., 2012-2018
Table 79 Pfizer Inc. Vaccine Pipeline in the U.S.
Table 80 U.S.: Macroindicators
Table 81 U.S.: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 82 U.S.: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 83 U.S.: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 84 U.S.: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 85 Canada: Macroindicators
Table 86 Canada: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 87 Canada: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 88 Canada: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 89 Canada: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 90 Europe: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 91 Europe: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 92 Europe: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 93 Europe: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 94 Europe: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 95 Germany: Macroindicators
Table 96 Germany: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 97 Germany: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 98 Germany: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 99 Germany: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 100 U.K.: Macroindicators
Table 101 U.K.: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 102 U.K.: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 103 U.K.: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 104 U.K.: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 105 France: Macroindicators
Table 106 France: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 107 France: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 108 France: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 109 France: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 110 Italy: Macroindicators
Table 111 Italy: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 112 Italy: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 113 Italy: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 114 Italy: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 115 Spain: Macroindicators
Table 116 Spain: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 117 Spain: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 118 Spain: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 119 Spain: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 120 RoE: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 121 RoE: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 122 RoE: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 123 RoE: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 124 Asia-Pacific: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 125 Asia-Pacific: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 126 Asia-Pacific: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 127 Asia-Pacific: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 128 Asia-Pacific: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 129 Japan: Macroindicators
Table 130 Japan: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 131 Japan: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 132 Japan: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 133 Japan: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 134 China: Macroindicators
Table 135 China: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 136 China: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 137 China: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 138 China: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 139 Cost of Some of the Vaccines in India
Table 140 India: Macroindicators
Table 141 India: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 142 India: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 143 India: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 144 India: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 145 RoAPAC: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 146 RoAPAC: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 147 RoAPAC: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 148 RoAPAC: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 149 Latin America: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 150 Latin America: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 151 Latin America: Vaccines Market Size, by Type, 2016–2025 ($Million)
Table 152 Latin America: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 153 Middle East & Africa: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 154 Middle East & Africa: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 155 Middle East & Africa: Vaccines Market Size, by Type, 2016–2025 ($Million)
Table 156 Middle East & Africa: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 157 Number of Developments by the Major Players During 2016-2019
Table 158 Vaccines Market: Product Competitive Benchmarking
Table 159 Vaccines Market: Geographic Competitive Benchmarking
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives interviewed
Figure 5 Breakdown of Primary interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth forecast Approach
Figure 7 Global Vaccines Market, by indication, 2019-2027 ($Million)
Figure 8 Global Vaccines Market Size, by Route of Administration, 2019-2027 ($Million)
Figure 9 Global Vaccines Market Size, by Antigen/Type, 2019-2027 ($Million)
Figure 10 Multivalent Vaccine Segment Will Dominate the Global Vaccines Market During the forecast Period
Figure 11 Vaccines Market, by Region
Figure 12 Products in Pipeline for infectious Diseases: 2018
Figure 13 Vaccines Projects in Pipeline: 2017
Figure 14 Disposable income Per Capita of China (in $): 2014-2018
Figure 15 Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010-2018
Figure 16 Decrease in Number of Tuberculosis Deaths: 2012-2017
Figure 17 Therapeutic Vaccines in Pipeline for Cancer: 2011 and 2018
Figure 18 New Cancer Cases in Asia, Latin America and Caribbean: 2018-2040
Figure 19 Vaccines Market, Product Pipeline, by Phase (2018)
Figure 20 Global Vaccines Market Size, by indication, 2019–2027 ($Million)
Figure 21 Influenza Vaccines Distribution: 2016-2019
Figure 22 Forecasted Global Demand of DTwP Vaccines: 2018-2032
Figure 23 MMR Vaccines Supply: 2016-2018
Figure 24 Global Vaccination Coverage for Rotavirus: 2010-2018
Figure 25 U.S. Funding for Global Polio: 2013-2019
Figure 26 Different Routes of Vaccine Administration
Figure 27 Vaccines Market Size, by Route of Administration, 2019–2027 ($Million)
Figure 28 Global Vaccines Market Size, by Type, 2019–2027 ($Million)
Figure 29 Global Vaccines Market Size, by Valence, 2019–2027 ($Million)
Figure 30 Global Vaccines Size, by Region, 2019-2027 ($Million)
Figure 31 North America: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 32 U.S. Funding for Global Polio: 2013-2019
Figure 33 Europe: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 34 Increase in Immunization After Mandatory Vaccination
Figure 35 Increase in Number of Registered influenza Cases (2015-2019)
Figure 36 Spain: increase in Number of Biotechnology Companies (2010-2016)
Figure 37 Asia-Pacific: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 38 India: Increasing Health Expenditure (2010-2018)
Figure 39 Cancer incidence in Middle East and Africa: 2012 and 2030
Figure 40 Key Growth Strategies Adopted by Leading Players -2016-2019
Figure 41 Global Vaccines Market Share, by Key Players, 2018 (%)
Figure 42 Vaccines Market Share Analysis, by Brand (2018)
Figure 43 Sanofi: Financial Overview (2016-2018)
Figure 44 Merck & Co., Inc.: Financial Overview (2016-2018)
Figure 45 GlaxoSmithKline Plc (GSK): Financial Overview (2016-2018)
Figure 46 Pfizer Inc.: Financial Overview (2016-2018)
Figure 47 Johnson & Johnson (J&J): Financial Overview (2016-2018)
Figure 48 Daichi Sankyo Co., Ltd.: Financial Overview (2016-2018)
Figure 49 Takeda Pharmaceutical: Financial Overview (2017-2019)
Figure 50 CSL Limited: Financial Overview (2017-2019)
Figure 51 Emergent BioSolutions Inc.: Financial Overview (2016-2018)
Figure 52 AstraZeneca: Financial Overview (2016-2018)
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2 Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market insights
4.1. Market Overview
4.2. Drivers
4.2.1. Strong Vaccines Pipeline
4.2.2. Rising Adoption of Vaccination
4.2.3. Increasing Government Focus on Immunization Programs
4.2.4. Technological Progress in Vaccine Administration
4.3. Restraints
4.3.1. High Cost Associated with Vaccine Development
4.3.2. Longer Timelines for Vaccine Manufacturing
4.4. Opportunities
4.4.1. Increasing Epidemic Potentials
4.4.2. Growing Focus on Therapeutic Vaccines
4.4.3. Growth Prospects in Emerging Markets
4.4.4. Increasing Use of Adjuvants in Vaccines
4.5. Challenges
4.5.1. Product Recalls
4.5.2. Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.1. Introduction
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papilloma Virus (HPV)
6.5. DTP
6.6. Meningococcal Disease
6.7. MMR
6.8. Rotavirus
6.9. Poliomyelitis (Polio)
6.10. Hepatitis
6.11. Other Indications
7. Global Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other (Routes of Administration)
8. Global Vaccines Market, by Type/Antigen
8.1. Introduction
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
8.6. Combination Vaccines
9. Global Vaccines Market, by Valence
9.1. Introduction
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Global Vaccines Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis
11.4.1. Market Share Analysis, by Company
11.4.2. Market Share Analysis, by Product
12. Company Profiles
12.1. Sanofi
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Pipeline Products
12.1.5. Strategic Developments
12.2. Merck & Co., Inc.
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.2.4. Pipeline Products
12.2.5. Strategic Developments
12.3. GlaxoSmithKline Plc.
12.3.1. Business Overview
12.3.2. Financial Overview
12.3.3. Product Portfolio
12.3.4. Pipeline Products
12.3.5. Strategic Developments
12.4. Pfizer, Inc.
12.4.1. Business Overview
12.4.2. Financial Overview
12.4.3. Product Portfolio
12.4.4. Pipeline Products
12.4.5. Strategic Developments
12.5. Johnson & Johnson
12.5.1. Business Overview
12.5.2. Financial Overview
12.5.3. Product Portfolio
12.5.4. Pipeline Products
12.5.5. Strategic Developments
12.6. Daiichi Sankyo Co., Ltd.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.3. Product Portfolio
12.6.4. Pipeline Products
12.7. Takeda Pharmaceutical Company Limited
12.7.1. Business Overview
12.7.2. Financial Overview
12.7.3. Product Portfolio
12.7.4. Pipeline Products
12.7.5. Strategic Developments
12.8. CSL Limited
12.8.1. Business Overview
12.8.2. Financial Overview
12.8.3. Product Portfolio
12.8.4. Pipeline Products
12.8.5. Strategic Developments
12.9. Emergent BioSolutions Inc.
12.9.1. Business Overview
12.9.2. Financial Overview
12.9.3. Product Portfolio
12.9.4. Pipeline Products
12.9.5. Strategic Developments
12.10. AstraZeneca
12.10.1.Business Overview
12.10.2.Financial Overview
12.10.3.Product Portfolio
12.10.4.Pipeline Products
13. Appendix
13.1. Questionnaire
13.2. Available Customization
List of Tables
Table 1 Global Vaccines Market Drivers: Impact Analysis (2019-2025)
Table 2 Key Government Regulatory Agencies
Table 3 List of Some of the Promising Vaccines in the Pipeline
Table 4 ASP of Key Vaccines, by Region ($ Per Unit)
Table 5 Global Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 6 Overview: Pneumococcal Disease
Table 7 Pneumococcal Diseases: Pipelined Vaccines
Table 8 Key Companies offering Pneumococcal Vaccines
Table 9 Pneumococcal Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 10 Overview: influenza Disease
Table 11 Influenza Diseases: Pipelined Vaccines
Table 12 Key Companies offering influenza Vaccines
Table 13 Influenza Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 14 Overview: HPV Disease
Table 15 HPV Vaccine Cost (2017)
Table 16 Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 17 Overview: Diphtheria, Tetanus, Pertussis Disease
Table 18 Global Supply of D&T by Product Group
Table 19 Key Companies offering DTP Vaccines
Table 20 DTP Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 21 Overview: Meningococcal Disease
Table 22 Marketed Meningococcal Vaccine Combinations
Table 23 Key Companies offering Meningococcal Vaccines
Table 24 Meningococcal Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 25 Overview: Measles, Mumps and Rubella Disease
Table 26 Key Companies offering MMR Vaccines
Table 27 MMR Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 28 Overview: Rotavirus Disease
Table 29 Key Companies offering Rotavirus Vaccines
Table 30 Rotavirus Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 31 Overview: Poliomyelitis Disease
Table 32 Polio Cases and Endemic Countries
Table 33 Key Companies offering Polio Vaccines
Table 34 Polio Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 35 Overview: Hepatitis A
Table 36 Overview: Hepatitis B
Table 37 Key Companies offering Hepatitis Vaccines
Table 38 Hepatitis Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 39 Other Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 40 Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 41 Intramuscular Sites of Vaccine Administration, by Age Group
Table 42 Vaccines for intramuscular Administration
Table 43 Key Companies offering intramuscular Vaccines
Table 44 Intramuscular Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 45 Site of Administration of Subcutaneous Vaccines by Age Group
Table 46 Vaccines for Subcutaneous Administration
Table 47 Key Companies offering Subcutaneous Vaccines
Table 48 Subcutaneous Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 49 Key Companies offering Oral Vaccines
Table 50 Oral Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 51 Other (Route of Administration) Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 52 Types of Vaccines, by Antigen
Table 53 Global Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 54 Companies offering Subunit & Conjugate Vaccines
Table 55 Subunit & Conjugate Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 56 Companies Offering Inactivated Vaccines
Table 57 Inactivated Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 58 Companies Offering Live Attenuated Vaccines
Table 59 Live Attenuated Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 60 Toxoid Vaccines Used in the Vaccination Schedule
Table 61 Companies Offering Toxoid Vaccines
Table 62 Toxoid Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 63 Companies offering Combination Vaccines
Table 64 Combination Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 65 Global Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 66 Available Multivalent Vaccines for Children
Table 67 Companies offering Multivalent Vaccines
Table 68 Multivalent Vaccines Market Size, by Region/Country, 2016–2025 ($Million)
Table 69 Malaria, Ebola and Dengue Disease Vaccines in Pipeline
Table 70 Companies offering Monovalent Vaccines
Table 71 Monovalent Vaccines Market Size, by Region/Country, 2017–2027 ($Million)
Table 72 Global Vaccines Market Size, by Country/ Region, 2017-2027 ($Million)
Table 73 North America: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 74 North America: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 75 North America: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 76 North America: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 77 North America: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 78 Influenza Burden in the U.S., 2012-2018
Table 79 Pfizer Inc. Vaccine Pipeline in the U.S.
Table 80 U.S.: Macroindicators
Table 81 U.S.: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 82 U.S.: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 83 U.S.: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 84 U.S.: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 85 Canada: Macroindicators
Table 86 Canada: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 87 Canada: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 88 Canada: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 89 Canada: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 90 Europe: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 91 Europe: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 92 Europe: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 93 Europe: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 94 Europe: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 95 Germany: Macroindicators
Table 96 Germany: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 97 Germany: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 98 Germany: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 99 Germany: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 100 U.K.: Macroindicators
Table 101 U.K.: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 102 U.K.: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 103 U.K.: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 104 U.K.: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 105 France: Macroindicators
Table 106 France: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 107 France: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 108 France: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 109 France: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 110 Italy: Macroindicators
Table 111 Italy: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 112 Italy: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 113 Italy: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 114 Italy: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 115 Spain: Macroindicators
Table 116 Spain: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 117 Spain: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 118 Spain: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 119 Spain: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 120 RoE: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 121 RoE: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 122 RoE: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 123 RoE: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 124 Asia-Pacific: Vaccines Market Size, by Country, 2017-2027 ($Million)
Table 125 Asia-Pacific: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 126 Asia-Pacific: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 127 Asia-Pacific: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 128 Asia-Pacific: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 129 Japan: Macroindicators
Table 130 Japan: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 131 Japan: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 132 Japan: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 133 Japan: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 134 China: Macroindicators
Table 135 China: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 136 China: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 137 China: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 138 China: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 139 Cost of Some of the Vaccines in India
Table 140 India: Macroindicators
Table 141 India: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 142 India: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 143 India: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 144 India: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 145 RoAPAC: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 146 RoAPAC: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 147 RoAPAC: Vaccines Market Size, by Type, 2017–2027 ($Million)
Table 148 RoAPAC: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 149 Latin America: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 150 Latin America: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 151 Latin America: Vaccines Market Size, by Type, 2016–2025 ($Million)
Table 152 Latin America: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 153 Middle East & Africa: Vaccines Market Size, by indication, 2017–2027 ($Million)
Table 154 Middle East & Africa: Vaccines Market Size, by Route of Administration, 2017–2027 ($Million)
Table 155 Middle East & Africa: Vaccines Market Size, by Type, 2016–2025 ($Million)
Table 156 Middle East & Africa: Vaccines Market Size, by Valence, 2017–2027 ($Million)
Table 157 Number of Developments by the Major Players During 2016-2019
Table 158 Vaccines Market: Product Competitive Benchmarking
Table 159 Vaccines Market: Geographic Competitive Benchmarking
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives interviewed
Figure 5 Breakdown of Primary interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth forecast Approach
Figure 7 Global Vaccines Market, by indication, 2019-2027 ($Million)
Figure 8 Global Vaccines Market Size, by Route of Administration, 2019-2027 ($Million)
Figure 9 Global Vaccines Market Size, by Antigen/Type, 2019-2027 ($Million)
Figure 10 Multivalent Vaccine Segment Will Dominate the Global Vaccines Market During the forecast Period
Figure 11 Vaccines Market, by Region
Figure 12 Products in Pipeline for infectious Diseases: 2018
Figure 13 Vaccines Projects in Pipeline: 2017
Figure 14 Disposable income Per Capita of China (in $): 2014-2018
Figure 15 Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010-2018
Figure 16 Decrease in Number of Tuberculosis Deaths: 2012-2017
Figure 17 Therapeutic Vaccines in Pipeline for Cancer: 2011 and 2018
Figure 18 New Cancer Cases in Asia, Latin America and Caribbean: 2018-2040
Figure 19 Vaccines Market, Product Pipeline, by Phase (2018)
Figure 20 Global Vaccines Market Size, by indication, 2019–2027 ($Million)
Figure 21 Influenza Vaccines Distribution: 2016-2019
Figure 22 Forecasted Global Demand of DTwP Vaccines: 2018-2032
Figure 23 MMR Vaccines Supply: 2016-2018
Figure 24 Global Vaccination Coverage for Rotavirus: 2010-2018
Figure 25 U.S. Funding for Global Polio: 2013-2019
Figure 26 Different Routes of Vaccine Administration
Figure 27 Vaccines Market Size, by Route of Administration, 2019–2027 ($Million)
Figure 28 Global Vaccines Market Size, by Type, 2019–2027 ($Million)
Figure 29 Global Vaccines Market Size, by Valence, 2019–2027 ($Million)
Figure 30 Global Vaccines Size, by Region, 2019-2027 ($Million)
Figure 31 North America: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 32 U.S. Funding for Global Polio: 2013-2019
Figure 33 Europe: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 34 Increase in Immunization After Mandatory Vaccination
Figure 35 Increase in Number of Registered influenza Cases (2015-2019)
Figure 36 Spain: increase in Number of Biotechnology Companies (2010-2016)
Figure 37 Asia-Pacific: Vaccines Market Size, by Country, 2019-2027 ($Million)
Figure 38 India: Increasing Health Expenditure (2010-2018)
Figure 39 Cancer incidence in Middle East and Africa: 2012 and 2030
Figure 40 Key Growth Strategies Adopted by Leading Players -2016-2019
Figure 41 Global Vaccines Market Share, by Key Players, 2018 (%)
Figure 42 Vaccines Market Share Analysis, by Brand (2018)
Figure 43 Sanofi: Financial Overview (2016-2018)
Figure 44 Merck & Co., Inc.: Financial Overview (2016-2018)
Figure 45 GlaxoSmithKline Plc (GSK): Financial Overview (2016-2018)
Figure 46 Pfizer Inc.: Financial Overview (2016-2018)
Figure 47 Johnson & Johnson (J&J): Financial Overview (2016-2018)
Figure 48 Daichi Sankyo Co., Ltd.: Financial Overview (2016-2018)
Figure 49 Takeda Pharmaceutical: Financial Overview (2017-2019)
Figure 50 CSL Limited: Financial Overview (2017-2019)
Figure 51 Emergent BioSolutions Inc.: Financial Overview (2016-2018)
Figure 52 AstraZeneca: Financial Overview (2016-2018)